Vyome Holdings (HIND) Interest & Investment Income (2015 - 2025)
Vyome Holdings (HIND) posted Interest & Investment Income of $18000.0 for Q2 2025, up 145.0% on a QoQ basis from -$40000.0 in Q1 2025, and up 350.0% year-over-year from $4000.0 in Q2 2024.
Powered by 
Analysis
Vyome Holdings (HIND) Interest & Investment Income (2015 - 2025) Analysis & Trends
Vyome Holdings has reported Interest & Investment Income for 11 years, with the latest figure at $18000.0 in Q2 2025.
- On a quarterly basis, Interest & Investment Income rose 350.0% year-over-year to $18000.0 in Q2 2025; TTM through Jun 2025 was -$21000.0, a 160.0% decrease from a year earlier, with the FY2024 full-year figure at $14000.0, down 46.15% from the prior year.
- Interest & Investment Income was $18000.0 for Q2 2025 at Vyome Holdings, up from -$40000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $31000.0 in Q3 2022, with the low at -$599000.0 in Q1 2021.
- Average Interest & Investment Income over 5 years is -$54588.2, with a median of $1000.0 recorded in 2022.
- The sharpest annual moves came in 2021 and 2025: Interest & Investment Income slumped 1811.43% in 2021, then soared 350.0% in 2025.
- Over 5 years, Interest & Investment Income stood at -$28000.0 in 2021, then sank by 471.43% to -$160000.0 in 2022, then soared by 110.62% to $17000.0 in 2023, then slumped by 94.12% to $1000.0 in 2024, then surged by 1700.0% to $18000.0 in 2025.
- The last three Interest & Investment Income figures came in at $18000.0 (Q2 2025), -$40000.0 (Q1 2025), and $1000.0 (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 120.60 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -48.00 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 48.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 67.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 36.92 Mn |
| 10 | Vyome Holdings | 14.46 Mn | 6.57 Mn | 11,658.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 18,000.00 |
| Mar 31, 2025 | -40,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Jun 30, 2024 | 4,000.00 |
| Mar 31, 2024 | 9,000.00 |
| Dec 31, 2023 | 17,000.00 |
| Sep 30, 2023 | 5,000.00 |
| Jun 30, 2023 | 9,000.00 |
| Mar 31, 2023 | -5,000.00 |
| Dec 31, 2022 | -160,000.00 |
| Sep 30, 2022 | 31,000.00 |
| Jun 30, 2022 | 14,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Dec 31, 2021 | -28,000.00 |
| Sep 30, 2021 | -33,000.00 |
| Jun 30, 2021 | -172,000.00 |
| Mar 31, 2021 | -599,000.00 |
| Dec 31, 2020 | -417,000.00 |
| Sep 30, 2020 | -739,000.00 |
| Jun 30, 2020 | -789,000.00 |